Covid 19 Research using Clinical Trials (Home Page)
Report for D012170: Retinal Vein Occlusion NIH
(Synonyms: Retinal Vein Occl, Retinal Vein Occlusion)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug724 | Data collection up to 1 year Wiki | 1.00 |
| drug1978 | Questionnaire Wiki | 0.21 |
Correlated MeSH Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008268 | Macular Degeneration NIH | 0.71 |
| D008269 | Macular Edema NIH | 0.71 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012636 | Retinal vein occlusion HPO | 1.00 |
| HP:0011505 | Cystoid macular edema HPO | 0.71 |
There is one clinical trial.
Clinical Trials
1 Collateral Damage From the COVID-19 Pandemic Observed in Patients Treated With Intravitreal Injections (IVT) of Anti-angiogenic Agents
In patients treated for exudative age-related macular degeneration (AMD), diabetes, retinal venous occlusion (OVR), or other conditions causing macular edema, treatments with anti-angiogenic intravitreal injections (IVT) are widely used both for their anti-angiogenic action. Patients often have injections for many years, sometimes monthly or every 2 months. The discontinuation of treatment with repeated injections of anti-angiogenic agents, linked to the COVID-19 coronavirus pandemic will potentially impact the visual acuity, the ophthalmological state and the quality of life of the patients concerned, therefore it is relevant to analyze the consequences the breakdown of usual care in this population.
NCT04395859 Age Related Macular Degeneration Diabetic Macular Edema Retinal Vein Occlusion Procedure: Questionnaire Other: Data collection up to 1 year MeSH:Macular Degeneration Macular Edema Retinal Vein Occlusion
HPO:Cystoid macular edema Macular edema Retinal vein occlusion
Primary Outcomes
Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up
Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic Time: Baseline (Before confinement) and 6 months after resumption of follow-up
HPO Nodes
Primary Outcomes
Description: Change from baseline (last visual acuity before confinement) and visual acuity 6 months after resumption of follow-up
Measure: Change of visual acuity in patients treated with repeated IVT anti-angiogens during the COVID-19 epidemic Time: Baseline (Before confinement) and 6 months after resumption of follow-up